NeuroOne Medical Technologies Corporation: 10-Q filed 2018-08-13
What NeuroOne Medical Technologies Corporation reported in its quarterly report filed 2018-08-13 (fiscal Q2 2018): 22 published measures, 51 facts as tagged in accession 0001213900-18-010817.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2018-08-13
- Fiscal period
- fiscal Q2 2018
- Accession
- 0001213900-18-010817 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NeuroOne Medical Technologies Corporation filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 229,696 | USD | |
| At 2017-12-31 | 249,985 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 7,518,237 | USD | |
| At 2017-12-31 | 5,286,596 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | -7,288,541 | USD | |
| At 2017-12-31 | -5,036,611 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | -1,260,986 | USD | 91 |
| 2018-01-01 to 2018-06-30 | -2,617,760 | USD | 181 |
| 2017-04-01 to 2017-06-30 | -1,294,323 | USD | 91 |
| 2017-01-01 to 2017-06-30 | -2,023,899 | USD | 181 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-06-30 | -1,294,859 | USD | 181 |
| 2017-01-01 to 2017-06-30 | -913,166 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-06-30 | 1,346,000 | USD | 181 |
| 2017-01-01 to 2017-06-30 | 812,511 | USD | 181 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-06-30 | -55,000 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | -7,942,556 | USD | |
| At 2017-12-31 | -5,324,796 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-06-30 | 373,947 | USD | 181 |
| 2017-01-01 to 2017-06-30 | 11,849 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | -1,172,214 | USD | 91 |
| 2018-01-01 to 2018-06-30 | -2,269,694 | USD | 181 |
| 2017-04-01 to 2017-06-30 | -888,689 | USD | 91 |
| 2017-01-01 to 2017-06-30 | -1,404,747 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 23,227 | USD | |
| At 2017-12-31 | 33,613 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 3,302,261 | USD | |
| At 2017-12-31 | 3,905,131 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 82,193 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 206,469 | USD | |
| At 2017-12-31 | 216,372 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | 1,172,214 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 2,269,694 | USD | 181 |
| 2017-04-01 to 2017-06-30 | 888,689 | USD | 91 |
| 2017-01-01 to 2017-06-30 | 1,404,747 | USD | 181 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | 225,529 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 330,574 | USD | 181 |
| 2017-04-01 to 2017-06-30 | 156,716 | USD | 91 |
| 2017-01-01 to 2017-06-30 | 228,757 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 8,014,994 | shares | |
| At 2017-12-31 | 7,864,994 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 646,000 | USD | |
| At 2017-12-31 | 280,320 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 206,469 | USD | |
| At 2017-12-31 | 216,372 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2018-06-30 | 1,478,678 | USD | |
| At 2017-12-31 | 1,021,617 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-04-01 to 2018-06-30 | 946,685 | USD | 91 |
| 2018-01-01 to 2018-06-30 | 1,939,120 | USD | 181 |
| 2017-04-01 to 2017-06-30 | 731,973 | USD | 91 |
| 2017-01-01 to 2017-06-30 | 1,175,990 | USD | 181 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2018-01-01 to 2018-06-30 | 9,906 | USD | 181 |
Inspect the source
- Entity
- NeuroOne Medical Technologies Corporation / CIK 0001500198
- Captured
- 2026-09-20T09:11:29.314Z
- SEC response SHA-256
dec08ad6d59f8d84b3a6db4a6ff83df3a276b794fed82089495b0788055433dd
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001500198.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))